Cell therapy manufacturing automation market seen topping $3 billion by 2030

The cell therapy manufacturing automation market is forecast to pass $3 billion by 2030, driven by faster commercialization, tighter quality rules and the push for scalable production. North America is expected to remain the largest regional market, while hardware keeps the biggest share of spending.

Why it matters: - Cell therapy makers are under pressure to scale production without sacrificing quality or compliance. - Automation is becoming central to that shift because manual workflows are harder to standardize, validate and expand. - The market’s projected growth signals rising demand for the tools needed to manufacture personalized and allogeneic therapies at commercial scale.

What happened: - The Business Research Company projected the global cell therapy manufacturing automation market will surpass $3 billion by 2030. - The market is expected to grow at a 13% CAGR through 2030. - North America is forecast to remain the largest regional market in 2030 at $1.3 billion, up from $0.7 billion in 2025. - The United States alone is projected to reach $1.1 billion by 2030. - Thermo Fisher Scientific Inc. led global sales in 2025 with a 5% market share. - Thermo Fisher Scientific introduced gibco CTS cellmation software in January 2024 for cell therapy manufacturing automation.

The details: - Hardware is expected to be the largest component segment in 2030, accounting for 47% of the market, or about $2 billion. - Hardware growth is tied to automated cell processing instruments, sterile single-use devices, and high-throughput systems for cell isolation and expansion. - The market also includes software and services. - Cell types covered include T-cells, stem cells and natural killer cells. - Process segments include upstream processing, downstream processing, fill-finish and quality control. - End users include pharmaceutical and biotechnology companies, research institutions and contract manufacturing organizations. - The market’s combined hardware, software and services segments are expected to add more than $2.3 billion in value by 2030. - Hardware and software are each projected to add about $1 billion between 2025 and 2030. - Services are expected to add about $0.3 billion in the same period. - The report highlighted automation features such as validated digital connectivity, DeltaV automation and integrated instrument control in Thermo Fisher Scientific’s cellmation platform.

Between the lines: - Rapid commercialization is forcing manufacturers to move beyond manual processes. - Automated systems help reduce contamination risk, human error and production variability. - Regulatory pressure is also pushing adoption because automated workflows support traceability, electronic records and GMP compliance. - The market is moderately fragmented, with the top 10 players accounting for 25% of revenue in 2025. - That fragmentation suggests room for partnerships, product development and geographic expansion as the sector matures.

What's next: - Growth is expected to come from integrated automated platforms, real-time monitoring, digital quality control tools and manufacturing execution systems. - The market should also benefit from outsourced integration and validation services, closed-system production and AI-driven monitoring. - North America’s lead is likely to continue as biopharma firms and contract manufacturers expand GMP-compliant capacity. - Major players include Lonza, Catalent, WuXi AppTec, Corning, Sartorius, Fujifilm, Miltenyi Biotec, Merck KGaA, Danaher’s Cytiva and others.

The bottom line: - Cell therapy manufacturing automation is moving from a niche capability to a core manufacturing requirement as the industry scales.